MorphoSys builds out U.S. infrastructure for anticipated launch of lymphoma drug

The German drugmaker plans to submit its data package for FDA approval by the end of the year, with potential approval next year. The package will include a synthetic control arm comprising real-world data.

Continue reading on MedCityNews

By MIT Sloan CDO
MIT Sloan CDO Profile Picture